North America Blau Syndrome Market - Industry Trends and Forecast to 2027

Report ID: | Publihed: 07-Jan-2020 | No of Pages: 80


USD 3995
USD 5795

Publish Date:


Total pages:


North America Blau syndrome market is projected to register a healthy CAGR of 12.3% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.
Market Segmentation:
North America Blau Syndrome Market, By Type (Treatment and Diagnosis), Therapeutic Areas (Skin Rash, Inflammation), Route of Administration (Oral, Parenteral, Topical, Others), End User (Hospitals, Diagnostic Centers, Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico) Industry Trends & Forecast to 2020
Some of the major factors contributing to the growth of North America Blau syndrome market are:

• High adoption of biological therapies
• Availability of off label drugs
Market Players:

The key market players for North America Blau syndrome market are listed below:

• Novartis AG
• Pfizer Inc.
• AbbVie Inc.
• Amgen Inc.
• Janssen Pharmaceuticals, Inc (A Subsidiary of Johnson & Johnson Services Inc.)
• Mylan N.V.
• Hikma Pharmaceuticals PLC
• Teva Pharmaceutical U.S.A Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.)
• Fulgent Genetics Inc.
• Invitae Corporation,
• Swedish Orphan Biovitrum AB
• Alkem Labs.
• F. Hoffmann-La Roche Ltd
• Zydus Pharmaceuticals (USA) Inc. (a subsidiary of Zydus cadila)
• Amneal Pharmaceuticals LLC
• Salix Pharmaceuticals (a subsidiary of Bausch Health Companies Inc.)
• Centogene AG
• Oncodesign

Report Subsumes the following

Competitors Analysis Go To Market Strategies
Regional Coverage with precise Market Numbers Global Impact post Covid-19
Market Penetration Strategies Granular breakdown By Type and By Application.